Sandoz Group Ag News - 0SAN

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Ad hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Ad hoc announcement...

Sandoz reports first quarter 2024 sales

Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first...

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of...

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Ad hoc announcement pursuant to art...

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering Ad hoc announcement pursuant to...

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines MEDIA RELEASE EUR 50m...

Sandoz reports fourth quarter 2023 sales and full-year 2023 results

Sandoz reports fourth quarter 2023 sales and full-year 2023 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA...

Sandoz receives FDA approval for first and only denosumab biosimilars

Sandoz receives FDA approval for first and only denosumab biosimilars MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz...

Sandoz announces nominations to the Board of Directors and leadership change

Sandoz announces nominations to the Board of Directors and leadership change Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing...

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market MEDIA RELEASE CIMERLI®*, a...

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs Ad hoc announcement pursuant...

Sandoz announces changes in the Board of Directors

Sandoz announces changes in the Board of Directors Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme...

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany Ad hoc announcement pursuant to art. 53 SIX...

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market Ad hoc announcement pursuant to...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Sandoz Group Ag (0SAN)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

0SAN News

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz reports first quarter 2024 sales

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

Sandoz reports fourth quarter 2023 sales and full-year 2023 results

Sandoz receives FDA approval for first and only denosumab biosimilars

Sandoz announces nominations to the Board of Directors and leadership change

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs

Sandoz announces changes in the Board of Directors

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

0SAN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Sandoz Group Ag (0SAN) News

Sandoz Group Ag (0SAN)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

0SAN News

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz reports first quarter 2024 sales

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

Sandoz reports fourth quarter 2023 sales and full-year 2023 results

Sandoz receives FDA approval for first and only denosumab biosimilars

Sandoz announces nominations to the Board of Directors and leadership change

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs

Sandoz announces changes in the Board of Directors

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

0SAN Discussion

Your Recent History